drugset / Trial / NCT00231192

Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes

NCT00231192

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD in adolescents. In addition, successful treatment of CFRD with repaglinide will improve nutritional status, ameliorate declines in pulmonary function, and will not have a negative impact upon quality of life.

Timeline

Start
2005-10
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic
Subject Repaglinide Small molecule Oral

Indications